Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Baxter
Colorcon
Argus Health
Federal Trade Commission
Julphar

Generated: August 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,054,574

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,054,574
Title: Plant ubiquitin promoter system
Abstract:A DNA segment from the upstream untranscribed region of a maize ubiquitin gene is disclosed. This ubiquitin promoter region, which comprises heat shock consensus elements, initiates and regulates the transcription of genes placed under its control. Recombinant DNA molecules are also described in which a ubiquitin promoter is combined with a plant expressible structural gene for regulated expression of the structral gene and for regulated control of expression when stressed with clevated temperatures. Such recombinant DNA molecules are introduced into plant tissue so that the promoter/stuctural gene combination is expressed.
Inventor(s): Quail; Peter H. (Richmond, CA), Christensen; Alan H. (Albany, CA), Hershey; Howard P. (West Chester, PA), Sharrock; Robert A. (El Cerrito, CA), Sullivan; Thomas D. (Madison, WI)
Assignee: Mycogen Plant Science, Inc. (San Diego, CA)
Application Number:09/094,350
Patent Claims:1. A DNA fragment approximately 2 kb in length, said DNA fragment comprising a plant ubiquitin regulatory system, wherein said regulatory system contains a promoter comprising a transcription start site, one or more heat shock elements positioned 5' to said transcription start site, and an intron positioned 3' to said transcription start site, wherein said regulatory system is capable of regulating constitutive and inducible gene expression in both dicots and monocots such that the level of said constitutive gene expression in monocots is about one-third that obtained in said inducible gene expression in monocots.

2. A DNA fragment as in claim 1, wherein said heat elements are at least 50% homologous to the Drosophila heat shock consensus sequence and function to increase expression of a gene under its control under heat shock conditions.

3. A DNA fragment as in claim 2, wherein said heat shock elements are at least 75 % homologous to the heat shock consensus sequence.

4. A DNA fragment as in claim 2, wherein said regulatory system contains at least two heat shock elements.

5. A DNA fragment as in claim 4, wherein at least two of said heat shock elements overlap.

6. A DNA as in claim 5, wherein the extent of overlap in said overlapping heat shock elements is 5 nucleotides.

7. A DNA fragment as in claim 1, wherein said intron is approximately 1 kb in length.

8. A DNA fragment as in claim 7, wherein said intron is that of the maize ubiquitin regulatory system.

9. A recombinant DNA construct comprising:

a. A DNA fragment approximately 2 kb in length, said DNA fragment comprising a plant ubiquitin regulatory system, wherein said plant ubiquitin regulatory system contains a promoter comprising a transcription start site, one more heat shock elements positioned 5' to said transcription start site, a translational start site, and an intron positioned 3' to said transcription start site and 5' to said translational start site, wherein said plant ubiquitin regulatory system is capable of regulating constitutive and inducible gene expression in both dicots and monocots such that said constitutive gene expression in monocots is at a level about one-third that obtained in said inducible gene expression in monocots, and

b. a plant-expressible heterologous structural gene positioned 3' to said plant ubiquitin regulatory system and a polyadenylation signal positioned 3' to said structural gene, wherein said heterologous gene is placed under the regulatory control of said plant ubiquitin regulatory system.

10. A recombinant DNA construct as in claim 9, wherein said heat shock elements are approximately 200 nucleotides 5' of the transcription start site.

11. A recombinant DNA construct as in claim 10, wherein said regulatory system contains two heat shock elements.

12. A recombinant DNA construct as in claim 10, wherein said heat shock elements overlap.

13. A recombinant construct as in claim 12, wherein the extent of overlap in said overlapping heat shock elements is, approximately 5 nucleotides.

14. A recombinant DNA construct as in claim 9, wherein said intron is approximately 1 kb in length.

15. A recombinant DNA construct as in claim 14, wherein said intron is that of the maize ubiquitin regulatory system.

16. A recombinant DNA construct as in claim 9, wherein said structural gene codes for chloramphenicol acetyl transferase.

17. A recombinant DNA construct as in claim 9, wherein said heat shock elements are at least 50% homologous to the Drosophila heat shock consensus sequence.

18. A DNA fragment, useful in effecting expression in both monocots and dicots of coding sequences placed 3' to said fragment, wherein said DNA is isolated or incorporated into a larger piece of DNA but in a position other than in the 5' sequence of a plant ubiquitin gene, is approximately 2 kb in length, and said DNA fragment further comprises, in the following order beginning with the 5' most element and proceeding toward the 3' terminus of said DNA fragment:

(a) one or more heat shock elements, which elements may or may not be overlapping;

(b) a promoter comprising a transcription start site; and

(c) an intron of about 1 kb in length;

and wherein said DNA fragment comprising said elements (a)-(c) is capable of regulating gene expression in both dicots and monocots.

19. The DNA fragment of claim 18 wherein:

(a) there are two heat shock elements which overlap;

(b) the promoter has the sequence of the promoter shown in FIG. 2, or functional truncations thereof; and

(c) the intron is as shown in FIG. 2 between the transcription start site and the translation start site, or replacements or truncations thereof which do not alter the usefulness of said DNA fragment in effecting expression in both monocots and dicots of coding sequences placed 3' to said fragment.

Details for Patent 6,054,574

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Try a Free Trial Mycogen Plant Science, Inc. (San Diego, CA) 2008-05-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Try a Free Trial Mycogen Plant Science, Inc. (San Diego, CA) 2008-05-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Try a Free Trial Mycogen Plant Science, Inc. (San Diego, CA) 2008-05-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Julphar
Chubb
Harvard Business School
Citi
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.